# Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy

> **NCT04480450** · PHASE2 · WITHDRAWN · sponsor: **University of Kansas Medical Center**

## Conditions studied

- Chronic Inflammatory Demyelinating Polyneuropathy

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT04480450
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to acquire funding
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480450, "Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04480450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*